Skip to Content

Generic Veregen Availability

Veregen is a brand name of sinecatechins topical, approved by the FDA in the following formulation(s):

VEREGEN (sinecatechins - ointment;topical)

  • Manufacturer: FOUGERA PHARMS INC
    Approval date: October 31, 2006
    Strength(s): 15% [RLD]

Has a generic version of Veregen been approved?

No. There is currently no therapeutically equivalent version of Veregen available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Veregen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Composition for treating Condyloma acuminata
    Patent 5,795,911
    Issued: August 18, 1998
    Inventor(s): Cheng; Shu Jun & Wang; De Chang & Hara; Yukihiko
    Assignee(s): Cancer Institute (Hospital), Chinese Academy of Medical Sciences Mitsui Norin Co., Ltd.
    A composition for a treatment of HPV-infected Condyloma acuminata which comprises containing tea catechin as a main component. This medication has no danger of side-effects and may be easily applied to or inserted in the infected area by the patient themselves.
    Patent expiration dates:
    • October 31, 2020
      ✓ 
      Patent use: TREATMENT OF GENITAL WARTS
  • Medicament for the treatment of viral skin and tumour diseases
    Patent 7,858,662
    Issued: December 28, 2010
    Inventor(s): Chang; Yunik & Lathrop; Robert & Böhm; Erwin & Gander-Meisterernst; Irene & Greger; Regina & Holldack; Johanna & Moebius; Ulrich
    Assignee(s): MediGene AG
    The invention relates to a medicament containing a compound of general formula (1), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkynyl group, preferably a C11-C15 alkyl, alkylene or alkynyl group, particularly a C11-C13 alkyl, alkylene or alkynyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkynyl group, preferably a C1-C6 alkyl, alkylene or alkynyl group, in particular a C2-C4 alkyl, alkylene or alkynyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m—O]nH group with n=1 to 10, preferably n=1 to 5, m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p[CH2—(R3)]— group, where R3=independent H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof.
    Patent expiration dates:
    • October 2, 2026
      ✓ 
      Patent use: TREATMENT OF GENITAL WARTS
      ✓ 
      Drug product
  • Medicament for the treatment of viral skin and tumour diseases
    Patent 9,770,406
    Issued: September 26, 2017
    Assignee(s): Medigene AG
    The invention relates to a medicament containing a compound of general formula (I), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkinyl group, preferably a C11-C15 alkyl, alkylene or alkinyl group, particularly a C11-C13 alkyl, alkylene or alkinyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkinyl group, preferably a C1-C6 alkyl, alkylene or alkinyl group, in particular a C2-C4 alkyl, alkylene or alkinyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m-O]nH group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p[CH2—R3]- group, where R3=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof.
    Patent expiration dates:
    • July 12, 2025
      ✓ 
      Patent use: TREATMENT OF GENITAL WARTS
      ✓ 
      Drug product
Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide